Therapeutics, or coming up with the next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.
- Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community for over 20 years.
- Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
- The fund is structured to be EIS compliant providing income, inheritance and capital gains tax breaks for UK taxpayers.
| Fund Size | Target £ 10m |
|---|---|
| Tax Advantages | Under new "Approved EIS funds" investor are eligible for added tax advantages. A carry-back rule enable investors to set their relief against income tax liabilities in the year before the fund closes. |
| Diversification | Aim to build investors an initial Portfolio of 5-10 unquoted and/or AIM-listed companies. |
| Tax Relief | 30% income tax relief * |
For more details on the fund, please download fund documents
For more details on the fund, please download fund documents
EIS tax relief is very attractive for UK tax payers
You invest £50k
EIS gives you £15k tax relief from HMRC
EIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
£15k income tax relief
£10k performance incentive
£55k net profit
Investment still worth £50k
£0 profit
£15k income tax relief
£0 performance incentive
£15k net profit
Investment now worth £0
£50k loss
£15k income tax relief
£15,750 loss relief *
£0 performance incentive
£19,250 capital loss
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
Need help in understanding how investing in EIS works?
Need help in understanding how investing in EIS works?
Subscribe to Get Latest Updates on Our Portfolio Companies
o2h Ventures Named Runner-Up for Best EIS Investment Manager — Specialist at the 2025 Growth Investor Awards 13 November, 2025
o2h Ventures Participates in Oversubscribed Seed Round to Advance CamGene Therapeutics’ RNA-Based Medicines 3 November, 2025- o2h Ventures Portfolio Update: Monument Therapeutics Reaches Landmark Milestone in Schizophrenia 23 August, 2025
